This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysts Name Top Biotech Stocks for 2010: BioBuzz

Either way, the search for a new Biogen CEO, which the company said is already underway, will be an interesting process to watch. Now that Mullen is essentially a lame duck, it's reasonable to expect the company's board -- including Icahn's proxies -- to take a more active management role.

Naturally, speculation will increase that Biogen could be placed back on the sale block.

It might be lost amidst all the palace intrigue, but Mullen did manage to bring home a 12% return for shareholders in 2009 -- making Biogen the only big-cap biotech stock to close the year in the green.

Still, Biogen does face challenges ahead with the increase in the number of cases of the serious brain infection known as PML tied to use of its multiple sclerosis drug Tysabri. The company has also experienced setbacks recently with its late-stage drug pipeline.

Biogen shares closed Monday at $53.64, ahead of the announcement of Mullen's retirement.

Help Wanted: Big-Cap Biotech CEO

Running a multi-billion dollar, profitable biotech firm isn't a position that comes available very often, which makes the search for a new CEO at Biogen Idec a relatively rare event.

Mullen joined Biogen in 1989 and rose to the CEO post in 2000, the same year that Amgen's (AMGN) current CEO Kevin Sharer also took over the top job at his company.

Genzyme's (GENZ) CEO Henri Termeer is the longest-serving CEO in the big-cap biotech group, named to the position in 1985. (How long he stays there is also an intriguing question for 2010.)

John Martin became Gilead Sciences (GILD) CEO in 1996, while Celgene (CELG) CEO Sol Barer is a relative newcomer, having been promoted to his position in 2006. (Although Barer's tenure with Celgene began in 1987.)

5 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs